Brief: Corbus Pharmaceuticals Reports Updated Crb-701 Phase 1/2 Clinical Data Demonstrating Robust Activity In 2L Oropharyngeal And Cervical Cancers
26/05/2026 12:10
May 26 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O: CORBUS PHARMACEUTICALS REPORTS UPDATED CRB-701 PHASE 1/2 CLINICAL DATA DEMONSTRATING ROBUST ACTIVITY IN 2L OROPHARYNGEAL AND CERVICAL CANCERS CORBUS PHARMACEUTICALS HOLDINGS INC - CRB-701 GENERALLY SAFE AND WELL TOLERATED WITH DISCONTINUATION RATES BELOW 3% Source text: ID:nGNX2tH2Lb Further company coverage: CRBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study